argenx SE (ARGX) shares fell over 10% on October 8, 2026, after the company stopped its Phase 3 UNITY trial of subcutaneous Vyvgart for Sjögren's disease due to futility. An independent committee found the study unlikely to meet its primary endpoint, prompting discontinuation. Despite positive Phase 2 results for another drug, FB102, in celiac disease, the stock declined sharply. A securities law investigation has been announced for shareholders who suffered losses, with legal firm Levi & Korsinsky offering no-cost evaluations for potential claims.
Regarding argenx and its recent developments, here is Pluang's health sector market snapshot as of Oct 09, 2026 02:02 WIB: Among 128 priced health-sector US stocks tradable on Pluang, 40 rose and 88 fell. Notable movers include Summit Therapeutics Inc (SMMT) at USD 17.26 with a 1-day change of -3.84%, Crispr Therapeutics AG (CRSP) at USD 50.48 with a 1-day change of -3.57% and a Pluang order activity of 77% Sell / 23% Buy, and Cardinal Health Inc (CAH) at USD 240.26 with a 1-day change of +3.49% and 100% buy order activity. The most notable figure is the 88 stocks that fell today.
SpaceX is expanding its AI infrastructure to support its rocket launches, Starlink satellite network, and future AI growth plans. Analysts show mixed but generally positive sentiment, with Morgan Stanley maintaining a Buy rating and a $300 price targ...
Byrna Technologies reported a fiscal Q3 loss of $0.13 per share, better than the expected $0.16 loss, but revenue fell 46% year-over-year to $15.3 million, missing estimates. The company shifted from net income to a $2.9 million net loss due to weake...
On October 8, 2026, several stocks including AngioDynamics, Apimeds Pharmaceuticals US, and Arqit Quantum experienced steep declines of over 18%, despite some positive financial reports. Leveraged ETFs CRWG and IRE also dropped 15.5%, highlighting th...
On October 8, 2026, Pacira BioSciences surged 44.4% following Viatris' agreement to acquire the company for $36.50 per share, valuing the deal at approximately $1.65 billion. Other notable gainers included Profound Medical, which rose 21.7% after for...
Njord Luxco, a major shareholder jointly controlled by entities under Brookfield Corporation, has sold all its shares and voting rights in TORM plc as of October 6, 2026. This marks a significant change in TORM's shareholder structure, potentially im...
